NUAK2, upregulated in ovarian surfaceepithelium in proestrus and predicted to have a driver mutation in ovariancancer, was examined in a larger cohort of serous ovarian cancer where patientswith lower NUAK2 expression had shorter overall survival. This evidence concerns the gene NUAK2 and ovarian serous adenocarcinoma.